2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5401 Age, not disease burden, drives first-line choice of treatment intensity in MYC/BCL2-rearranged high-grade B-cell lymphoma: A real world cohort and expert survey

Rebecca Wurm-Kuczera, MD, Atef Abdelhafez2, Lisa Fischer3, Markus Maulhardt, MD4, Alexandra Kutilina5, Susanne Ghandili6, Emin Abdullayev7, Evgenii Shumilov I, MD8, Nina Walburg9, Vanja Zeremski, MD10, Marcel Teichert, MSc11, Flavio Pistolese12, Inna Shaforostova, MD13, Joseph Kauer14, Isabelle Krämer15, Tonio Brinkschmidt, MD16, Thomas Oellerich, MD17, Peter Dreger, Prof. Dr. med.18, Thomas Melchardt, MD19, Urban Novak20, Carmelo Carlo-Stella, MD21, Bastian von Tresckow, MD22, Dimitrios Mougiakakos23, Georg Lenz, MD24, Bertram Glass, MD25, Carsten Bokemeyer, MD26, Reinhard Marks, MD27, Gerald Wulf28, Ulrich Keller29, Björn Chapuy, MD30
1 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
3 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4 University Medical Center Goettingen, Goettingen, Germany
5 University of Freiburg, Freiburg, Germany
6 University Medical Center Hamburg-Eppendorf, Hamburg-Eppendorf, Germany
7 Helios Klinikum Berlin-Buch, berlin, Germany
8 University Hospital Muenster, Muenster, Germany
9 University Hospital Muenster, Muenster, Germany
10 University Hospital Magdeburg, Magdeburg, Germany
11 West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
12 Humanitas University, milan, Italy, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy
13 Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
14 Heidelberg University Hospital, Heidelberg, Germany
15 Heidelberg University Hospital, Heidelberg, Germany
16 University Hospital Frankfurt, Goethe University, Frankfurt, Germany
17 Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main, Germany, German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
18 Heidelberg University Hospital, Heidelberg, Germany
19 Austrian Group for Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria, Paracelsus Medical University, Salzburg, Austria
20 Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
21 Humanitas University, milan, Italy, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy
22 West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
23 University Hospital Magdeburg, Magdeburg, Germany
24 University Hospital Muenster, Muenster, Germany
25 Helios Klinikum Berlin-Buch, berlin, Germany
26 University Medical Center Hamburg-Eppendorf, Hamburg-Eppendorf, Germany
27 University of Freiburg, Freiburg, Germany
28 University Medical Center Goettingen, Goettingen, Germany
29 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Cluster of Excellence ImmunoPreCept, Charité - Universitätsmedizin Berlin, berlin, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, Max Delbrück Center for Molecular Medicine, berlin, Germany
30 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

High-grade B-cell lymphoma (HGBCL) is an aggressive malignancy with unfavorable outcomes under standard regimens. Diagnostic heterogeneity and evolving WHO classifications leave HGBCL inconsistently defined across trials and real-world analyses (RWA). Consequently, no frontline (1L) consensus standard of care exists. Clinicians choose among R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP, and Burkitt-like protocols (± consolidative autologous stem cell transplantation [autoSCT]) without robust guidance for treatment selection. This ambiguity is particularly pronounced in elderly or unfit patients, routinely excluded from trials evaluating intensified regimens. We evaluated real-world 1L clinical outcomes and the parameters driving treatment selection in HGBCL, combining a European multi-center cohort study with a global physician survey.

Across 13 European centers (2014–2025), we assembled a FISH-confirmed cohort of HGBCL patients treated with curative 1L intent. Patients with aggressive large B-cell lymphoma harboring concurrent MYC and BCL2 and/or BCL6 rearrangements were included. HGBCL patients with previously treated transformed low-grade lymphoma were excluded. 1L intensity was classified as intensified- (DA-EPOCH-R/R-CHOEP/Burkitt-type ± autoSCT), standard- (R-CHOP/Pola-R-CHP), or attenuated-intensity (R-mini-CHOP/GMALL-elderly). AutoSCT was modeled separately using time-dependent Cox regression (adjusted for age and comorbidity) to avoid immortal-time bias. Predictors of intensity were assessed by multivariable logistic regression. To capture physicians' perspective, we surveyed 89 hematologists/oncologists managing HGBCL.  

Our RWA comprised 184 HGBCL patients: 108 DHL-BCL2 with MYC and BCL2 translocation, 36 DHL-BCL6 with MYC and BCL6 translocation, and 40 THL with MYC and BCL2 and BCL6 translocations. Median age was 63 years (22-84; 21% >70y); 62%(113/182) had intermediate-high/high risk (IPI>3); bone marrow (BM) involvement was present in 38% (66/173); 39% (69/179) had bulky disease (>7.5cm), 31%(53/173) had transformed from an indolent lymphoma; 88% (97/110) were GCB-type by Hans; median age-adjusted Charlson Comorbidity Index (aCCI) was 3 (range: 0-9). 1L therapy included 33% standard, 56% intensified, and 11% attenuated regimens.

Consistent with prior reports, DHL-BCL6 lymphomas trended to better progression free survival (PFS) compared to DHL-BCL2 (p=0.3); no difference between DHL-BCL2 or THL was noted. Among 122 previously untreated HGBCL patients, 1L standard R-CHOP-like regimens yielded significantly inferior PFS (P = 0.001) and a trend toward inferior overall survival (OS; P = 0.061) compared to intensified regimens. After excluding auto SCT recipients from the intensified group, this difference did not remain significant. However, the 23 fit, chemo-sensitive autoSCT patients had excellent 5-year PFS/OS (78.1% and 95.7%), remaining significant in time-dependent Cox modeling (HR 0.07, 95% CI 0.01–0.51, P=0.009). 

Patients >70y predominantly received standard R-CHOP-like regimens (86% vs. 28%), while patients <70y received more frequent intense regimens (48% vs. 14%) and autoSCTs consolidation (25% vs. 0%). Despite data indicating that chronological age should not preclude patients from intensified regimens, our multivariable analysis highlights age as the predominant selection factor rather than IPI, aCCI or ECOG for induction treatment selection (OR 0.19, P=0.003) and autoSCT (OR 0.35, P=0.022). 

In our survey, only 6% (n=5) experts routinely administered DA-EPOCH-R as 1L therapy for patients aged 60–80 years; 18% (16) restricted its use to fit patients, 30% (27) used it only case-by-case, and 45% (40) preferred alternative regimens in this age group.  R-mini-CHOP was the most frequently used alternative, reported by 89% experts. Reasons for withholding DA-EPOCH-R were poor performance status (ECOG >2, 71%), comorbidities (67%), and cardiovascular risk (56%). Despite this reliance on clinical risk factors, 51% of respondents used no formal comprehensive geriatric or comorbidity assessment tool, and functional evaluation relied almost exclusively on ECOG (88%).

In summary, chronological age—rather than objective comorbidity or disease risk—is the primary driver of 1L treatment attenuation and exclusion from intensified therapies possibly resulting in decreased outcomes. Prospective randomized trials in HGBCL using standardized patient selection criteria are urgently needed.

Rebecca Wurm-Kuczera, MD: No relevant conflicts of interest to declare.